eIF4E-eIF4G complex inhibition synergistically enhances the effect of sorafenib in hepatocellular carcinoma

The clinical efficacy of sorafenib in hepatocellular carcinoma (HCC) is disappointing due to its low response rate and high rates of adverse effects. The eukaryotic translation initiation factor 4F (eIF4F) complex, mainly consisting of eIF4E-eukaryotic translation initiation factor 4G (eIF4G) intera...

Descripción completa

Detalles Bibliográficos
Autores principales: Fang, Chao, Xie, Haishen, Zhao, Jun, Wang, Weichen, Hou, Hui, Zhang, Bin, Zhou, Dachen, Geng, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Preclinical Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366763/
https://www.ncbi.nlm.nih.gov/pubmed/33783376
http://dx.doi.org/10.1097/CAD.0000000000001074

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366763/
https://www.ncbi.nlm.nih.gov/pubmed/33783376
http://dx.doi.org/10.1097/CAD.0000000000001074

Ejemplares similares